{"entity":{"id":"cardiff-oncology","kind":"company","name":"Cardiff Oncology","aka":["Trovagene","Cardiff Oncology, Inc.","NASDAQ:CRDF"],"tldr":"Cardiff Oncology is a San Diego biotech developing onvansertib, an oral PLK1 inhibitor that is being tested with chemotherapy and bevacizumab as first-line treatment for RAS-mutant colorectal cancer.","summary":"Cardiff Oncology, formerly the diagnostics company Trovagene, develops onvansertib, a selective oral inhibitor of Polo-like kinase 1 licensed from Nerviano Medical Sciences. The randomised phase 2 CRDF-004 trial combines onvansertib with FOLFIRI or FOLFOX plus bevacizumab in first-line RAS-mutant metastatic colorectal cancer, after earlier studies showed higher response rates in bevacizumab-naive patients. Onvansertib has also been studied in pancreatic cancer and small cell lung cancer.","asOf":"2026-09-17","links":[{"label":"Official website","url":"https://www.cardiffoncology.com/"}],"tags":["drug-maker"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":["onvansertib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo drug-maker linking round (corporate websites and regulatory records)","editedOn":"2026-09-17"},"hq":"San Diego, California","country":"US","companyType":"biotech","website":"https://www.cardiffoncology.com/","ticker":"NASDAQ:CRDF","stage":"public","investors":[],"funding":[]},"route":"/companies/cardiff-oncology/","neighbours":{"drug":[{"id":"onvansertib","kind":"drug","name":"Onvansertib","route":"/drugs/onvansertib/"}]}}